Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PTPRZ1 | P23471 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.35 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896343 | 0.93 | TDP1 (0.86) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL22452926 | 0.84 | ALDH1A1 (0.70) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL11298765 | 0.82 | ALDH1A1 (0.70) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL8639823 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL12012131 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL25118394 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL698212 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL10361212 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL10978325 | 0.76 | ALDH1A1 (0.61) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 | |
| SCHEMBL7940607 | 0.76 | ALDH1A1 (0.61) | ALDH1A1TDP1KDM4EPTPRZ1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 579 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119613279-A | N-substituted benzene ring bioisostere and preparation method thereof | 上海交通大学 | 2025-03-14 | — | — | CN | claimed |
| CN-117105830-A | Fluorination method of p-nitrophenyl methyl sulfide | 江苏永创医药科技股份有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117105829-A | Chlorination method of p-nitrophenyl methyl sulfide | 江苏永创医药科技股份有限公司 | 2023-11-24 | — | — | CN | claimed |
| US-20230337447-A1 | QUANTUM DOT LIGHT EMITTING DEVICE AND MANUFACTURING METHOD THEREFOR, AND DISPLAY DEVICE | Beijing Boe Technology Development Co., Ltd. (CN) | 2023-10-19 | — | — | US | claimed |
| CN-115394930-A | Light-emitting device, preparation method thereof and display device | 北京京东方技术开发有限公司 | 2022-11-25 | — | — | CN | claimed |
| WO-2022062718-A1 | QUANTUM DOT LIGHT EMITTING DEVICE AND MANUFACTURING METHOD THEREFOR, AND DISPLAY DEVICE | 京东方科技集团股份有限公司 | 2022-03-31 | — | — | WO | claimed |
| US-10991972-B2 | Electrolyte solution, positive electrode, and lithium-ion battery comprising the electrolyte solution and/or the positive electrode | BYD COMPANY LIMITED (CN) | 2021-04-27 | — | — | US | claimed |
| US-20190036156-A1 | ELECTROLYTE SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY COMPRISING THE ELECTROLYTE SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD COMPANY LIMITED (CN) | 2019-01-31 | — | — | US | claimed |
| EP-3407416-A1 | ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY CONTAINING THE ELECTROLYTIC SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD Company Limited (CN) | 2018-11-28 | — | — | EP | claimed |
| CN-106609137-A | Dark blue organic light-emitting material and preparation method and application thereof | 北京大学深圳研究生院 | 2017-05-03 | — | — | CN | claimed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 1695/4885TDP1 4707/4885KDM4E 3926/4885 |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | ALDH1A1 899/4885TDP1 4073/4885KDM4E 2679/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | ALDH1A1 843/4885TDP1 1724/4885KDM4E 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.